Cryptogenic stroke patients with patent foramen ovale should be closed only in the setting of a randomized control trial

Catheterization and Cardiovascular Interventions

Volumn 69, Issue 1, 2007, Pages 4-5

  Felberg, Robert A ^a  

^a OCHSNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; EVIDENCE BASED MEDICINE; HEART ANEURYSM; HEART ATRIUM SEPTUM DEFECT; HIGH RISK POPULATION; HUMAN; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; PATHOGENESIS; PATIENT REFERRAL; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SHORT SURVEY; STROKE;

CEREBROVASCULAR ACCIDENT; EMBOLISM, PARADOXICAL; HEART SEPTAL DEFECTS, ATRIAL; HUMANS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS;

EID: 33845981820     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.20726     Document Type: Short Survey

References (11)

1. Lechat P, Mas JL, Lascault G, Loron P, Theard M, Klimczac M, Drobinski G, Thomas D, Grosgogeat Y. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 1988; 318:1148-1152.
2. Furlan AJ, Patent foramen ovale and recurrent stroke: Closure is the best option: Yes. Stroke 2004;35:803-804.
3. Mas JL, Arquizan C, Lamy C, Zuber M, Cabanes L, Derumeaux G, Coste J, Patent Foramen Ovale and Atrial Septal Aneurysm Study Group. Recurrent cerebrovasculur events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 2001;345:1740-1746.
4. Homma S, Sacco RL, DiTullio MR, Sciacca RR, Mohr JP, for the PFO in Cryptogenic Stroke Study (PICSS) Investigators. Effect of medical treatment in stroke patients with patent foramen ovale: Patent Foramen Ovale in Cryptogenic Stroke Study. Circulation 2002;105:2625-2631.
5. The EC/IC Bypass Study Group. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. Results of an international randomized trial. N Engl J Med 1985; 313:1191-1200.
6. The Ischemic Optic Neuropathy Decompression Trial Research Group. Optic nerve decompression surgery for nonarteritic anterior ischemic optic neuropathy (NAION) is not effective and may be harmful. JAMA 1995;273:625-632.
7. Ferrari J, Baumgartner H, Tentschert S, Dorda V, Lang W, Willfort-Ehringer A, Probst P, Lalouschek W. Cerebral microembolism during transcatheter closure of patent foramen ovale. J Neurol 2004;251:825-829.
8. Anzola GP, Morandi E, Casilli F, Onorato E. Does transcatheter closure of patent foramen ovale really "shut the door?" A prospective study with transcranial Doppler. Stroke 2004;35:2140-2144.
9. Anzai H, Child J, Natterson B, Krivokapich J, Fishbein MC, Chan VK, Tobis JM. Incidence of thrombus formation on the CardioSEAL and the Amplatzer interatrial closure devices. Am J Cardiol 2004;93:426-431.
10. Amin Z, Hijazi ZM, Bass JL, Cheatham JP, Hellenbrand WE, Kleinman CS Erosion of Amplatzer septal occluder device after closure of secundum atrial septal defects: Review of registry of complications and recommendations to minimize future risk. Catheter Cardiovasc Interv 2004;63:496-502.
11. Wahl A, Krumsdorf U, Meier B, Sievert H, Ostermayer S, Billinger K, Schwerzmann M, Becker U, Seiler C, Arnold M, Mattle HP, Windecker S. Transcatheter treatment of atrial septal aneurysm associated with patent foramen ovale for prevention of recurrent paradoxical embolism in high-risk patients. J Am Coll Cardiol 2005;45:377-380.